These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparative disposition of sulindac and metabolites in five species. Duggan DE; Hooke KF; Noll RM; Hucker HB; Van Arman CG Biochem Pharmacol; 1978; 27(19):2311-20. PubMed ID: 103551 [No Abstract] [Full Text] [Related]
3. Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. Duggan DE; Hooke KF; Hwang SS Drug Metab Dispos; 1980; 8(4):241-6. PubMed ID: 6105058 [TBL] [Abstract][Full Text] [Related]
4. Identification of the biologically active form of sulindac. Duggan DE; Hooke KF; Risley EA; Shen TY; Arman CG J Pharmacol Exp Ther; 1977 Apr; 201(1):8-13. PubMed ID: 850147 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of graded oral doses of sulindac in man. Mattila J; Mäntylä R; Vuorela A; Lamminsivu U; Männistö P Arzneimittelforschung; 1984; 34(2):226-9. PubMed ID: 6539116 [TBL] [Abstract][Full Text] [Related]
7. Sulfoxide reduction. In vitro reduction of sulindac by rat hepatic cytosolic enzymes. Ratnayake JH; Hanna PE; Anders MW; Duggan DE Drug Metab Dispos; 1981; 9(2):85-7. PubMed ID: 6113122 [TBL] [Abstract][Full Text] [Related]
8. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium. Duggan DE Drug Metab Rev; 1981; 12(2):325-37. PubMed ID: 7040018 [TBL] [Abstract][Full Text] [Related]
9. In vitro metabolism of sulindac and sulindac sulfide: enzymatic formation of sulfoxide and sulfone. Kitamura S; Tatsumi K Jpn J Pharmacol; 1982 Oct; 32(5):833-8. PubMed ID: 7176218 [TBL] [Abstract][Full Text] [Related]
10. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism. Lin JH; Yeh KC; Duggan DE Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111 [TBL] [Abstract][Full Text] [Related]
12. Thioredoxin-dependent sulfoxide reduction by rat renal cytosol. Anders MW; Ratnayake JH; Hanna PE; Fuchs JA Drug Metab Dispos; 1981; 9(4):307-10. PubMed ID: 6114827 [TBL] [Abstract][Full Text] [Related]
13. Dimethyl sulfoxide inhibits metabolic activation of sulindac. Swanson BN; Mojaverian P; Boppana VK; Vlasses PH; Ferguson RK Ann N Y Acad Sci; 1983; 411():381-2. PubMed ID: 6576719 [No Abstract] [Full Text] [Related]
14. The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Strong HA; Renwick AG; George CF; Liu YF; Hill MJ Xenobiotica; 1987 Jun; 17(6):685-96. PubMed ID: 3630204 [TBL] [Abstract][Full Text] [Related]
15. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion. Lin JH; Yeh KC; Duggan DE Drug Metab Dispos; 1985; 13(5):608-13. PubMed ID: 2865112 [TBL] [Abstract][Full Text] [Related]